Optimisation of chemotherapy in the era of immunotherapy

René Boosman, Jacobus (Sjaak) Adrianus Burgers

Source: Eur Respir J, 52 (4) 1801698; 10.1183/13993003.01698-2018

Journal Issue: October

Disease area: Thoracic oncology

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
René Boosman, Jacobus (Sjaak) Adrianus Burgers. Optimisation of chemotherapy in the era of immunotherapy. Eur Respir J, 52 (4) 1801698; 10.1183/13993003.01698-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Combination therapy in the era of immunotherapy Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Role of chemotherapy and radiation therapy Source: Annual Congress 2012 - PG10 An update on mesothelioma diagnostics and treatment Year: 2012
Concomitant radiotherapy and targeted therapies Source: International Congress 2019 – New perspectives in thoracic surgical oncology Year: 2019
Pitfalls of neoadjuvant treatment Source: Annual Congress 2012 - Current challenges in multimodality lung cancer treatment Year: 2012
Efficacy of induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): update of CT/RT 99/97 Source: Annual Congress 2004 - Management of lung cancer and innovative therapies Year: 2004
Surgery in the era of immune and targeted therapy Source: Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care Year: 2021
Adjuvant therapy in NSCLC Source: Annual Congress 2007 - Clinical year in review Year: 2007
Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017
Neoadjuvant chemotherapy for NSCLC, lung function and surgical therapy – which is their connection? Source: International Congress 2019 – Lung function testing: from experimental investigations to clinical applications Year: 2019
Combination immunotherapy in mesothelioma: managing expectations and new toxicities Source: Virtual Congress 2021 – Lung cancer grand round Year: 2021
First-line therapy Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
Adjuvant and neoadjuvant therapy in nonsmall cell lung cancer (NSCLC) Source: Annual Congress 2006 - Clinical year in review Year: 2006